Document Detail


Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure.
MedLine Citation:
PMID:  21062973     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Diminished serum arylesterase activity, catalyzed by the high-density lipoprotein-associated paraoxonase-1, is associated with heightened systemic oxidative stress and atherosclerosis risk. In the present study, we sought to determine the prognostic role of serum arylesterase activity in subjects with systolic heart failure, particularly in relation to established cardiac biomarkers.
METHODS AND RESULTS: We measured serum arylesterase activity in 760 subjects with impaired left ventricular systolic function (left ventricular ejection fraction <50%), and prospectively followed major adverse cardiac events (including death, nonfatal myocardial infarction, and stroke) for 3 years. In our study cohort (mean age, 64±11 years; 74% men; median left ventricular ejection fraction, 35%; median creatinine clearance, 96 mg/dL), mean serum arylesterase activity (98±25 μmol/L/min/mL) was lower compared with that in healthy control subjects (mean, 115±26 μmol/L/min/mL, P<0.01) but higher compared with advanced decompensated heart failure subjects (mean, 69±22 μmol/L/min/mL, P<0.01). Within our cohort, there was modest correlation between serum arylesterase activity and high-density lipoprotein cholesterol (r=0.33, P<0.01) as well as B-type natriuretic peptide (r=-0.23, P<0.01). Lower serum arylesterase activity was a strong predictor of poorer outcomes (hazard ratio, 2.94; 95% confidence interval, 1.54, 5.62; P<0.001). After adjusting for traditional risk factors, medication use, B-type natriuretic peptide, and creatinine clearance, lower serum arylesterase still conferred an increased risk of major adverse cardiac events at 3 years (hazard ratio, 2.69; 95% confidence interval, 1.37 to 5.28; P=0.004).
CONCLUSIONS: In patients with systolic heart failure, decreased serum arylesterase activity, a measure of diminished antioxidant properties of high-density lipoprotein, predicts higher risk of incident long-term adverse cardiac event independent of established clinical and biochemical risk factors.
Authors:
W H Wilson Tang; Yuping Wu; Shirley Mann; Michael Pepoy; Kevin Shrestha; Allen G Borowski; Stanley L Hazen
Related Documents :
15921813 - Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in pati...
5129313 - Quantitative assessment of the extent of myocardial infarction in the conscious dog by ...
8557903 - Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrat...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-11-09
Journal Detail:
Title:  Circulation. Heart failure     Volume:  4     ISSN:  1941-3297     ISO Abbreviation:  Circ Heart Fail     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-19     Completed Date:  2011-02-17     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  101479941     Medline TA:  Circ Heart Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  59-64     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antioxidants / metabolism*
Aryldialkylphosphatase / metabolism*
Biological Markers / blood
Carboxylic Ester Hydrolases / blood
Case-Control Studies
Cohort Studies
Disease Progression*
Female
Follow-Up Studies
Heart Failure, Systolic / complications,  metabolism*
Humans
Lipoproteins, HDL / metabolism*
Longitudinal Studies
Male
Middle Aged
Myocardial Infarction / epidemiology
Predictive Value of Tests
Prognosis
Prospective Studies
Risk Factors
Stroke / epidemiology
Stroke Volume / physiology
Ventricular Dysfunction, Left / complications,  metabolism*
Grant Support
ID/Acronym/Agency:
1P01 HL098055-01/HL/NHLBI NIH HHS; 1R01 DK080732-01A1/DK/NIDDK NIH HHS; 1R01 HL103931-01/HL/NHLBI NIH HHS; 1UL1RR024989/RR/NCRR NIH HHS; P01 HL076491/HL/NHLBI NIH HHS; P01 HL076491-01/HL/NHLBI NIH HHS; P01 HL076491-055328/HL/NHLBI NIH HHS; P01 HL0870180-20001/HL/NHLBI NIH HHS; P50 HL077107-050004/HL/NHLBI NIH HHS; R01 HL103931/HL/NHLBI NIH HHS; UL1 RR024989/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Biological Markers; 0/Lipoproteins, HDL; EC 3.1.1.-/Carboxylic Ester Hydrolases; EC 3.1.1.2/arylesterase; EC 3.1.8.1/Aryldialkylphosphatase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exploring the mechanistic bases of heterosis from the perspective of macromolecular complexes.
Next Document:  Intrinsic cooperation between p16INK4a and p21Waf1/Cip1 in the onset of cellular senescence and tumo...